Skip to main content
Clinical Trials/TCTR20200928004
TCTR20200928004
Not yet recruiting
Phase 3

Effectiveness of a Self-Management Support Integratedwith the Mobile Health Application Program on Self-Management Behaviors, Blood Pressure, and Estimated Glomerular Filtration Rate among Persons with Chronic Kidney Disease Stage 3: A Randomized C

An Ethics Committee on Human Research, Research and Innovation Admisnistration Division0 sites40 target enrollmentSeptember 28, 2020

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Chronic kidney disease stage 3
Sponsor
An Ethics Committee on Human Research, Research and Innovation Admisnistration Division
Enrollment
40
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 28, 2020
End Date
September 30, 2021
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
An Ethics Committee on Human Research, Research and Innovation Admisnistration Division

Eligibility Criteria

Inclusion Criteria

  • 1\) Patients aged 18\-79 years and family member
  • 2\) CKD stage 3a (eGFR \= 45\-59 ml/min/1\.73 m2\) or 3b (eGFR \= 30\-44 ml/min/1\.73 m2\)
  • 3\) Co\-morbidity diseases which controllable (using clinical parameters from medical history). For example, a person with hypertension must have blood pressure \< 180/110 mmHg and without symptoms of hypertensive urgency or hypertensive crisis. A person with diabetes mellitus must have a blood sugar (FBS) level ≤ 250 mg/dl and without diabetic ketoacidosis etc.
  • 4\) Without cognitive impairment which screened by the Thai mental state examination (TMSE)
  • 5\) Having a mobile phone and ability in using mobile phone applications and internet access
  • 6\) Ability to read and write in Thai
  • 7\) Reside in Samut Prakan Province

Exclusion Criteria

  • 1\) The participants have advanced to stage 4 or 5 of CKD during the program.
  • 2\) The participants are having adjusted to increase the dose of the antihypertensive drug during the program.
  • Termination criteria:
  • 1\) The participants have a severe illness or are in a critical phase and must be hospitalized during the program.
  • 2\) The participants died during the program.
  • Withdrawal criteria:
  • 1\) The participants request to withdraw because they are inconvenient to participate in the research project as scheduled.

Outcomes

Primary Outcomes

Not specified

Similar Trials